Global Biopharma Layoffs November 2025Layoffs
Layoff
Novatis
AbbVie
Bayer
Merck
This article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Global Biopharma Layoffs October 2025Layoffs
Layoff
Novo Nordisk
Takeda
GSKThis article tracks recent biotech and pharma layoffs, including major workforce cuts at Novo Nordisk, Takeda, GSK, Pharming, and others, as companies restructure operations, streamline pipelines, and refocus resources amid shifting market conditions.
Bayer $1.3 Billion Collaboration AgreementBayer
Kumquat BiosciencesBayer and Kumquat Biosciences announce a $1.3 billion global collaboration to develop and commercialize a KRAS G12D inhibitor, aiming to offer new treatment options for pancreatic, colorectal, and lung cancer patients.
First Global DPP1 Inhibitor Approved by FDAFDA
InsmedThe FDA has approved brensocatib, the world’s first DPP1 inhibitor, for treating non-cystic fibrosis bronchiectasis in patients aged 12+, marking a breakthrough in targeted respiratory therapies.
Gilead Q2 2025 Financial ReportFinancial statements
GileadGilead's Q2 2025 results show strong HIV growth with Yeztugo approval but continued struggles in CAR-T therapies. Full-year guidance raised amid reliance on HIV business and strategic challenges ahead.